RETIPHARMA
RetiPharma is a Danish Biotech company that is developing products for treatment of degenerative eye disorders based on peptides that exerts neuroprotective effect in the eye.
RETIPHARMA
Industry:
Biotechnology Pharmaceutical
Founded:
2015-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.retipharma.com
Total Employee:
1+
Status:
Active
Contact:
(+45) 30 30 40 83
Total Funding:
1.3 M EUR
Technology used in webpage:
Content Delivery Network Domain Not Resolving Amazon DigiCert SSL CloudFront OpenResty AWS Global Accelerator Encryption Everywhere
Investors List
BioInnovation Institute
BioInnovation Institute investment in Venture Round - RetiPharma
More informations about "RetiPharma"
RetiPharma - Crunchbase Company Profile & Funding
RetiPharma is a Danish Biotech company that is developing products for treatment of degenerative eye disorders based on peptides that exerts neuroprotective effect in the eye. …See details»
RetiPharma - Products, Competitors, Financials, Employees, …
RetiPharma is a Copenhagen, Denmark-based company developing products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to …See details»
RP-003 - Drug Targets, Indications, Patents - Synapse - Patsnap
RP-003, Initially developed by Retipharma Ivs, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Eye Diseases, Active Indication: Eye Diseases, Active Org.: Retipharma Ivs.See details»
RetiPharma closes and sends asset back to founders
Nov 1, 2019 · Instead of continuing to build on the existing pharmaceutical concept, the asset is being sent back to the five founders from the University of Copenhagen and Rigshospitalet, Glostrup, to improve the efficacy of the …See details»
Retipharma Ivs - Drug pipelines, Patents, Clinical trials - Synapse
Explore the financial positions of over 360K organizations with Synapse. Access more than 2 million grant and funding information to elevate your research journey. Gain insights on the …See details»
BII News - Meet the start-ups: RetiPharma - BioInnovation Institute
Sep 20, 2018 · RetiPharma is one of the eight start-ups that joined BioInnovation Institute at the beginning of September. We had a talk with CEO Henrik Vissing about the first three weeks at …See details»
RetiPharma - Tech Stack, Apps, Patents & Trademarks - Crunchbase
RetiPharma is a Danish Biotech company. Start Free Trial . Chrome ExtensionSee details»
RP 003 - AdisInsight - Springer
Dec 28, 2022 · If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with …See details»
RetiPharma - VentureRadar
RetiPharma is a Biotech company focused on developing novel treatments for neurodegenerative eye diseases utilizing forward and backward... ... Find out more about RetiPharma, DNA, RNA …See details»
RetiPharma secures funding from the BII - NLS
Nov 13, 2018 · RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII) to develop treatments of degenerative eye disorders.See details»
Spin-out company from IN secures funding to develop treatments …
RetiPharma, a spin-out company formed by scientists at the Department of Neuroscience that focuses on the development of treatment of degenerative eye disorders has secured funding …See details»
RetiPharma Secures Funding to Develop Treatments of …
RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, is …See details»
RP-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 1, 2024 · Understand key drug designations in just a few clicks with Synapse. RP-001, Initially developed by Retipharma Ivs, Now, its global highest R&D status is Preclinical, …See details»
RP-003: Drug Targets, Indications, Patents - Synapse
RP-003, Initially developed by Retipharma Ivs, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Eye Diseases, Active Indication: Eye Diseases, Active Org.: Retipharma Ivs.See details»
RetiPharma Secures Funding to Develop Treatments of …
RetiPharma has announced that it has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII). The funding will be used to prepare its lead drug RP001 for a …See details»
RetiPharma Secures Funding to Develop Treatments of …
RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, isSee details»
RP-002 - Drug Targets, Indications, Patents - Synapse - Patsnap
Understand key drug designations in just a few clicks with Synapse. RP-002, Initially developed by Retipharma Ivs, Now, its global highest R&D status is Preclinical, Therapeutic Areas: Eye …See details»
RetiPharma to develop peptide drug for degenerative eye disorders
Nov 15, 2018 · RetiPharma, focusing on the development of products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to …See details»
RetiPharma completed a EUR 1,3M capital funding round from the …
RetiPharma, a Copenhagen, Denmark-based biotech startup focused on developing novel treatments for neurodegenerative eye diseases utilizing forward and backward translatability …See details»